Using DNA from the plasma of ESCC patients, Liu et al. analyzed the methylation status of Wnt antagonists SFRP1, DKK3, and RUNX3 and showed that patients carrying two or three of these hypermethylated genes had a significantly elevated risk of cancer recurrence, compared with those without methylated genes (46). This evidence concerns the gene RUNX3 and esophageal squamous cell carcinoma.